What Cadolac Treats: Main Uses and Benefits

Cadolac's therapeutic application centers on its capacity to offer support for significant symptomatic discomfort. It is commonly used in clinical settings where temporary, additional management of discomfort is required to support patient comfort during acute episodes. The medication is relevant for easing symptoms in conditions where a higher level of symptomatic support is appropriate for the management of acute discomfort.

---

Main Symptom Domains and Therapeutic Contexts

The medication is used for managing symptoms related to physical discomfort and inflammatory or irritative states. Specific conditions and scenarios where it is applied include moderate to severe acute pain following trauma or certain dental procedures, post-operative swelling and discomfort, or the localized symptoms of menstrual cramping. In its specialized topical form, it is also relevant for easing symptoms like inflammation and itching of the eye surface in contexts such as post-surgical care.

“This medication provides supportive relief that helps patients cope more steadily with pronounced symptoms during temporary, acute episodes.”

This application offers symptomatic relief that helps ease the overall symptom burden and may assist with functional stability during phases where symptoms create noticeable physiological strain.

---

Quick Fact: Relief for Acute Discomfort
Primary Focus	Managing symptoms of moderate to severe acute pain
Symptom Support	Contributes to easing pain and reducing inflammation
Key Scenarios	Post-operative care, trauma, localized ocular inflammation
Support Context	Relevant when short-term symptomatic assistance is needed

Regulatory References

1. NIH DailyMed overview of Ketorolac

Cadolac (ketorolac), a non-steroidal anti-inflammatory drug (NSAID), is approved for the short-term management of moderately severe acute pain, typically following surgery. The total duration of use, including both oral and injectable forms, should not exceed five days due to the risk of serious side effects.

---

Suitable Patients

Cadolac is generally prescribed for adults experiencing acute pain that requires potent analgesic relief. Patients must not have any contraindications to NSAIDs and must be carefully evaluated for pre-existing conditions that could increase the risk of adverse events.

---

Contraindications

Cadolac is not safe for use in several patient groups and conditions. These restrictions are in place because the drug significantly increases the risk of severe, potentially fatal, complications. You should not use Cadolac if you have:

• Hypersensitivity to ketorolac, aspirin, or other NSAIDs.
• Active or recent gastrointestinal bleeding or ulceration (peptic ulcer disease).
• Severe kidney impairment or are at risk for renal failure.
• A history of or currently have a high risk of bleeding, including suspected or confirmed cerebrovascular bleeding.
• Advanced heart failure or are undergoing Coronary Artery Bypass Graft (CABG) surgery (perioperative pain management).
• Pregnancy, particularly the third trimester, or are breastfeeding.
• Are under 18 years of age (pediatric use is not approved).
• Are currently taking aspirin or other NSAIDs, anticoagulants, or certain other medications.

Always discuss your complete medical history, including all medications and supplements, with your healthcare provider to ensure Cadolac is appropriate for your specific condition.

Cadolac, containing Ketorolac tromethamine, has several officially documented interaction patterns that are classified by regulatory agencies as either contraindicated or requiring close monitoring.

Contraindicated Combinations

Co-administration is strictly prohibited in regulatory documents for several substances due to heightened risk of adverse outcomes or altered drug exposure:

• Other NSAIDs and Aspirin: Use with other Nonsteroidal Anti-inflammatory Drugs, including aspirin, is contraindicated due to the cumulative risk of severe gastrointestinal complications and bleeding.
• Probenecid: Concomitant use is contraindicated because Probenecid reduces the clearance of Ketorolac, significantly increasing its plasma concentrations (AUC) and terminal half-life.
• Anticoagulants: The combination with full-dose anticoagulants (e.g., Warfarin) is contraindicated due to the synergistic increase in the risk of serious hemorrhage.

Other Documented Interactions

Other clinically significant interactions are described in official labeling:

• Exposure Modification: Ketorolac may elevate the plasma levels of Lithium and Methotrexate by reducing their renal clearance, potentially enhancing toxicity.
• Diuretics and Antihypertensives: Co-administration may reduce the natriuretic (salt-excreting) effect of Diuretics (e.g., Furosemide) and the effect of certain blood pressure medications (e.g., ACE Inhibitors), an effect attributed to the inhibition of renal prostaglandin synthesis.
• Alcohol: Official warnings advise against co-administration with Alcohol due to the additive risk of gastrointestinal irritation and bleeding.

This interaction profile mandates adherence to regulatory restrictions, particularly the strict prohibition of the contraindicated combinations and cautious use with drugs whose clearance or efficacy is affected by renal mechanisms.

How Cadolac Works

Cadolac's action is defined by its role as a non-selective enzyme inhibitor that targets the Cyclooxygenase (COX-1 and COX-2) enzymes . This interaction occurs in both peripheral tissues and within the central nervous system.

Blocking Prostaglandin Synthesis

Inhibiting the COX enzymes suppresses the initial enzymatic step in the arachidonic acid cascade, thereby preventing the conversion of arachidonic acid to key signaling molecules known as prostaglandins. Limiting the creation of these mediators changes the dynamics of the subsequent biochemical and cellular signaling sequence.

Modulating Signaling and Tissue Response

The resulting decrease in prostaglandin concentration influences both central and peripheral signaling dynamics. This mechanism contributes to a decrease in the responsiveness (sensitization) of nerve endings. The mechanism also restricts the prostaglandin-mediated dilation of blood vessels and fluid extravasation at cellular sites, modulating the body's local physiological response.

Cadolac (Ketorolac tromethamine) is administered systemically via intravenous (IV), intramuscular (IM), and oral routes, and locally via topical ophthalmic and, where approved, intranasal forms. Systemic use is limited to a maximum combined total duration of five days (parenteral plus oral), a core constraint that defines the medicine’s short-term role in clinical practice.

The systemic dosing regimen is tied to the route and the patient's clinical status. For adults under 65 years and over 50 kg, the typical multiple-dose IV or IM administration is 30 mg every 6 hours. Oral administration is defined as continuation therapy and not for initial use. The oral dose is typically 10 mg every four to six hours, with the maximum daily oral intake not to exceed 40 mg. The transition to oral dosing follows initial parenteral administration.

Administration protocols involve specific procedural conditions. For instance, the IV bolus is injected slowly, taking no less than 15 seconds to complete. Furthermore, the total daily systemic dose is reduced for specific populations, including individuals 65 years of age and older, patients with a body weight under 50 kg, and those with known renal impairment. For these groups, the maximum daily parenteral dose is 60 mg/day. These parameters govern the standardized administration and duration of the medication.

Research evidence / Overview of Studies for Cadolac

---

Evidence for Use in Short-term Management of Moderate to Severe Acute Pain

Research into the systemic use of Cadolac (Ketorolac tromethamine) primarily relies on Randomized Controlled Trials (RCTs). These studies examine adult patients with acute pain, such as after surgery or trauma, comparing the study medicine to a placebo or other active pain relievers. Researchers closely monitored outcomes related to physical discomfort, specifically measuring changes on pain intensity scales and tracked measurements of supplemental pain relief utilization.

The findings describe patterns observed in the studies where participants receiving the medicine reported measurements of supplemental pain relief over the initial monitoring periods compared to those receiving placebo. This research is generally focused on short-term symptom changes, usually over the first 24 hours up to the typical maximum treatment period of five days.

---

Evidence for Use in Ocular Inflammation and Pain

For the localized, ophthalmic (eye drop) form of Cadolac, research was evaluated in vehicle-controlled clinical trials in adult patients undergoing procedures like cataract surgery. These studies monitored outcomes linked to inflammatory or irritative states of the eye surface, as well as patient-reported outcomes describing perceived discomfort. This evidence contributes to the available evidence related to post-surgical inflammation and discomfort over a period of several weeks following the procedure.

---

Long-term Studies and Research Gaps

As the regulatory and research focus for Cadolac is strictly on short-term use, the research base predominantly reflects this constraint. Studies exploring short-term symptom changes provide limited information for long-term outcomes or the durability of symptom patterns. Consequently, follow-up durations were limited in most high-quality studies. The long-term effects are not fully established, and certainty remains low regarding outcomes past the initial five-day treatment window.

Research has explored various adult populations, but data are still emerging for certain subgroups like adolescents. One area of uncertainty is the specific findings of the drug in comparison to other non-opioid pain relief options, as comparative evidence is lacking in some head-to-head scenarios. Findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain.

Common questions about Cadolac (FAQ)

Q: What is Cadolac and how does it work?

A: Cadolac is a brand name for the drug ketorolac tromethamine. It belongs to a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). It is typically used for the short-term treatment of moderately severe acute pain that requires pain relief at the opioid level. Cadolac works by blocking the production of certain natural substances in the body that cause inflammation, pain, and fever.

---

Q: How is Cadolac usually given?

A: Cadolac is most often started as an injection (intramuscular or intravenous) in a healthcare setting, such as a hospital or doctor's office. This allows it to work quickly for severe pain. Treatment with the injected form is generally limited to no more than 5 days for safety reasons. In some cases, a patient may be switched to the oral tablet form after the initial injection, but the total treatment time (injection plus tablets) should not exceed 5 days.

---

Q: What is the maximum length of time I can take Cadolac?

A: Due to the risk of serious side effects, including gastrointestinal bleeding and kidney problems, the total duration of treatment with Cadolac (including any combination of injectable and oral tablets) should not be more than 5 days.

---

Q: What are the potential side effects of Cadolac?

A: Like all medications, Cadolac can cause side effects. Common side effects may include:

• Stomach upset or pain
• Nausea
• Drowsiness or dizziness
• Swelling (edema)
• Headache

More serious, but less common, side effects include a higher risk of serious gastrointestinal issues (bleeding, ulceration, perforation) and kidney problems. The risk of these serious side effects increases with higher doses or with treatment lasting longer than 5 days.

---

Q: Can I take Cadolac if I have a history of stomach ulcers or bleeding?

A: No, Cadolac should generally not be used if you have a history of recent or active peptic ulcer disease or gastrointestinal bleeding. Because Cadolac is an NSAID, it can increase the risk of serious stomach and intestinal side effects, such as bleeding or perforation. You must inform your healthcare provider about any history of ulcers or bleeding before taking this medication.

---

Q: Can Cadolac affect my kidneys?

A: Yes, Cadolac, like other NSAIDs, can potentially cause kidney problems, especially if you have existing kidney disease, heart failure, or are dehydrated. In some cases, it can cause acute kidney injury. This is a primary reason why the medication is approved only for short-term use (maximum 5 days).

---

Q: Is Cadolac a narcotic (opioid)?

A: No, Cadolac (ketorolac) is not a narcotic or an opioid. It is an NSAID (nonsteroidal anti-inflammatory drug). Although it provides potent pain relief comparable to some opioid medications, it works by a different mechanism and does not carry the same risk of dependence or addiction as opioids.

---

Q: Can I take other over-the-counter pain relievers while taking Cadolac?

A: You should not take other NSAIDs (such as ibuprofen, naproxen, or aspirin for pain relief) while taking Cadolac. Combining NSAIDs significantly increases the risk of side effects, particularly stomach bleeding and kidney damage. You should always check with your healthcare provider or pharmacist before taking any other pain relievers with Cadolac.

How to Store and Dispose of Cadolac?

The official storage requirements for Cadolac (Ketorolac tromethamine) are defined by the specific formulation to maintain potency and stability.

Storage Component	Requirement
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Injection Handling	Do not refrigerate or freeze the injection solution.
Protection	Protect all forms from light, and keep tablets away from excessive heat and moisture.
Packaging	Keep tablets in a tight, light-resistant container; retain injection vials in the original carton.
Post-Opening Stability	The injection solution is for single use only; discard any unused residue immediately after opening.
Child Safety	KEEP THIS AND ALL MEDICATIONS OUT OF THE SIGHT AND REACH OF CHILDREN.
Disposal	Dispose of unused or expired product and waste material in accordance with local regulatory requirements.

Disposal must be conducted in compliance with local regulations, and the product should not be emptied into household drains.